Dosing of PD-1 and PD-L1 inhibitors: Cost saving initiatives for significantly decreasing associated expenditure

Xin Yu J Hubbard VM Tang J. Immuno-oncology drug development goes global. Nat Rev Drug Discov 2019; 18: 899–900.

Chatelut E Le Louedec F Milano G. Setting the dose of checkpoint inhibitors: the role of clinical pharmacology. Clin Pharmacokinet 2020; 59: 287–296.

Shah NJ Kelly WJ Liu SV , et al. Product review on the anti-PD-L1 antibody. Hum Vaccin Immunother 2018; 14: 269–276.

Zhao X Suryawanshi S Hruska M , et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumours. Ann Oncol 2017; 28: 2002–2008.

Long GV Tykodi SS Schneider JG , et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol 2018; 29: 2208–2213.

Lala M Li M Sinha V , et al. A six-weekly (Q6H) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modelling and simulation. JCO 2018; 36: 3062–3062.

Novakovic AM Wilkins JJ Dai H , et al. Changing body weight-based dosing to a flat dose for avelumab in metastatic Merkel cell and advanced urothelial carcinoma. Clin Pharmacol Ther 2020; 107: 588–596.

Gilbar PJ Chambers CR Gilbar EC. Opportunities to significantly reduce expenditure associated with cancer drugs. Future Oncol 2017; 13: 1311–1322.

Gilbar PJ Chambers CR. How can we ensure value for money from expenditure on injectable cancer drugs? J Oncol Pharm Pract 2018; 24: 473–476.

Vaddepally RK Kharel P Pandey R , et al. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with level of evidence. Cancers 2020; 12: 738.

Renner A Burotto M Rojas C. Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy? J Glob Oncol 2020; 5: 1–5.

Bach PB Conti RM Muller RJ , et al. Overspending driven by oversized single dose vials of cancer drugs. BMJ 2016; 352: i788.

Ogungbenro K Patel A Duncombe R , et al. Dose rationalization of pembrolizumab and nivolumab using pharmacokinetic modelling and simulation and cost analysis. Clin Pharmacol Ther 2018; 103: 582–590.

Bayle A Besse B Annereau M , et al. Switch to anti-programmed cell death protein (anti-PD-1) fixed-dose regimen: what is the economic impact? Eur J Cancer 2019; 113: 28–31.

Clarenne J Boulanger C Marechal A , et al. Economical simulations for the optimal use of anti-programmed cell death-1 in advanced melanoma patients: report of a budget impact analysis. J Oncol Pharm Pract 2020; 26: 1216–1219.

Hall E Zhang J Kim EJ , et al. Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. Cancer Med 2020; 9: 2106–2112.

Ratain MJ Goldstein DA. Time is money: optimizing the scheduling of nivolumab. JCO 2018; 36: 3074–3076.

Goldstein DA Gordon N Davidescu M , et al. A pharmacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non-small cell lung cancer. J Nat Cancer Inst 2017; 109: djx063.

Jang A Nakashima L Ng T , et al. A real-world data approach to determine the optimal dosing strategy for pembrolizumab. J Oncol Pharm Pract. Epub ahead of print 15 June 2020. DOI: 10.1177/1078155220929756.

De Lemos ML Kung C Waignein S. Efficacy of nivolumab four-weekly dosing schedule based on body weight. J Oncol Pharm Pract 2019; 25: 961–963.

Hatswell AJ Porter JK. Reducing drug wastage in pharmaceuticals dosed by weight of body surface areas by optimizing vial sizes. Appl Health Econ Health Policy 2019; 17: 391–397.

Goldstein DA Ratain MJ Saltz LB. Weight-based dosing of pembrolizumab every 6 weeks in the time of COVID-19. JAMA Oncol. Epub ahead of print 27 May 2020. DOI: 10.1001/jamaoncol.2020.2493.

Topalian SL Hodi FS Brahmer JR , et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454.

Gilbar PJ Sung J Brown VJ , et al. Expanding the war on waste: recycling cancer drugs. J Pharm Pract Res 2019; 49: 454–459.

Gilbar PJ Chambers CR Vandenbrouche J , et al. How can the use of closed system transfer devices to facilitate sharing of drug vials be optimised to achieve maximum cost savings? J Oncol Pharm Pract 2019; 25: 205–209.